VERRICA PHARMACEUTICALS INC (VRCA)
US92511W1080 - Common Stock
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company...
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
NCE status provides a minimum of five years of regulatory exclusivity The Company’s U.S. patents and pending patent applications related to YCANTH™ are...
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
– Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives now covered on commercial insurance and...
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics...
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics...
Verrica sues to keep unapproved catharidin drugs off US market (NASDAQ:VRCA)
Verrica Pharmaceuticals (VRCA) has filed a lawsuit to stop Canadian drugmaker Dormer Labs from selling drugs containing cantharidin in the U.S. In the suit, Ver
Verrica sues to keep unapproved cantharidin drugs off US market (NASDAQ:VRCA)
Verrica Pharmaceuticals (VRCA) has filed a lawsuit to stop Canadian drugmaker Dormer Labs from selling drugs containing cantharidin in the U.S. In the suit, Ver
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
Lawsuit alleges false and misleading advertising and promotion of unapproved cantharidin-containing drugs by Dormer Laboratories in violation of federal...
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
WEST CHESTER, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics...
7 Potential Short-Squeeze Stocks Poised for Rapid Gains
Giving the bears a rough time can yield massive gains for contrarians, thus drawing attention to these potential short-squeeze stocks.
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need for new treatment options Company...
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
WEST CHESTER, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics...
Verrica Pharmaceuticals stock gains on Walgreens distribution deal (NASDAQ:VRCA)
Verrica Pharmaceuticals gains 5% as they partner with Walgreens for distribution of their dermatology product, Ycanth, treating molluscum contagiosum.
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
WEST CHESTER, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics...
Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today?
With Verrica Pharmaceuticals releasing positive Phase 3 trial results for a skin disease therapeutic, VRCA stock skyrocketed in response.
Verrica stock rallies 55% amid positive Phase 3 results for skin drug (NASDAQ:VRCA)
Verrica (VRCA) stock soared 55% Friday morning after Japanese development partner Torii reported positive Phase 3 study results for its skin infection drug. Read more here.
Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
WEST CHESTER, Pa., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics...